FIELD: biochemistry.
SUBSTANCE: present invention relates to biochemistry, particularly to a cyclic peptide possessing antineoplastic and antiangiogenic activity, having one of SEQ ID NO: 1-76. Present invention discloses a pharmaceutical composition, a pharmaceutical combination and use of said cyclic peptide for treating malignant growths or disorders associated with undesirable cell proliferation or undesirable angiogenesis. Pharmaceutical combination of said cyclic peptide in concentration of 12.5-200 mcM with anticancer drug in concentration of 1-2,000 nM has high antineoplastic activity. Present invention discloses means for diagnosis of malignant new growths, comprising a cyclic peptide and radiopharmaceutical agent, for example fluorescent particle.
EFFECT: present invention widens range of means of controlling malignant new growths.
14 cl, 21 dwg, 8 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT | 2006 |
|
RU2404808C2 |
| COMPOSITIONS AND METHODS FOR MALIGNANT NEOPLASMS PREVENTION AND TREATMENT | 2011 |
|
RU2623038C2 |
| HUMANISED ANTIBODIES AGAINST CD79b AND IMMUNOCONJUGATES AND METHODS OF APPLICATION | 2008 |
|
RU2557319C2 |
| ANTIBODIES AGAINST TENB2 CONSTRUCTED WITH CYSTEINE, AND CONJUGATES, ANTIBODY-DRUG | 2008 |
|
RU2505544C2 |
| VECTOR POLYPEPTIDE ANALOG OF TRANSFORMING GROWTH FACTOR ALPHA (TGF) FRAGMENT, ITS ANTITUMOR CONJUGATE AND PHARMACEUTICAL COMPOSITION ON CONJUGATE BASE | 2004 |
|
RU2277930C1 |
| ANTIBODY-DRUG CONJUGATES (ADC) WHICH BIND TO FLT3 PROTEINS | 2016 |
|
RU2739617C2 |
| IMMUNITY-INDUCING MEANS | 2012 |
|
RU2614386C2 |
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
| MODIFIED PROTEINS, CONSTRUCTED TOXINS AND METHODS FOR PRODUCTION THEREOF | 2002 |
|
RU2305684C2 |
| ANTICANCER PHARMACEUTICAL COMPOSITION (VERSIONS) AND APPLICATION THEREOF | 2005 |
|
RU2396274C2 |
